Table of Contents
DEVENS, Mass. — Bristol-Myers Squibb has completed a major expansion of its biologics facility in Devens, Mass.
The drug maker said the $280 million project will spur development of the company’s growing portfolio of biologics medicines.
Overall, Bristol-Myers has invested more than $1 billion into the Devens site.
With the expansion, the 89-acre Devens campus received two new buildings: a biologics development building for designing processes for the early production of investigational medicines, and a clinical manufacturing building where investigational medicines will be produced to support clinical trials.
Bristol-Myers noted that the buildings bring new capabilities to Devens, a site that previously had focused solely on large-scale, bulk biologics manufacturing.
“Biologics are increasingly important in the treatment of serious diseases and a rapidly growing part of our company’s pipeline of potential new therapies,” stated Lou Schmukler, president of global manufacturing and supply for Bristol-Myers Squibb. “Bringing together biologics development and clinical and commercial manufacturing on one campus will help accelerate the development of these innovative medicines for patients worldwide.”
The project also enlarges the site’s workforce, with about 200 new jobs having been added with the expansion’s completion. The company said that number will grow to approximately 350 jobs over time. The two new buildings add roughly 200,000 square feet to a site now comprised of eight major buildings in a 600,000-square-foot complex.
Bristol-Myers Squibb added that the expansion further boosts the major investment it has made at Devens, a former military base. Including the company’s initial $750 million investment to build the facility, the project brings the company’s total investment at the site to more than $1 billion.
“This project represents a significant expansion in the site’s size and mission,” commented Greg Guyer, senior vice president of biologics development and operations. “It creates one of the world’s premier, integrated biologics facilities, a biologics center of excellence for the company, for the Commonwealth of Massachusetts and for patients.”
The new buildings are reflect the company’s efforts to incorporate more efficient design and workspaces that foster collaboration and innovation, as well as further its commitment to sustainability. The biologics development building has received Leadership in Energy and Environmental Design (LEED) Silver certification for energy and environmental design, and the clinical manufacturing building is also targeted for LEED Silver certification.
